Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02314013
Other study ID # 2014-023
Secondary ID
Status Active, not recruiting
Phase N/A
First received November 20, 2014
Last updated November 14, 2016
Start date April 2014
Est. completion date February 2018

Study information

Verified date April 2016
Source Dongtan Sacred Heart Hospital
Contact n/a
Is FDA regulated No
Health authority Korea: Dontan Sacred Heart hospital Institutional Review Board/Ethics Committee
Study type Interventional

Clinical Trial Summary

The aim of the present study was to evaluate whether antibiotics is mandatory for the treatment of acute uncomplicated right-sided diverticulitis.

The hypothesis is that patients having acute uncomplicated diverticulitis at right-sided colon will be recovered without antibiotics.


Description:

All patients in the study were randomly allocated to one of the following two treatment groups; no-antibiotics group or antibiotics group.

Patients of no-antibiotics group were admitted to the ward and administered intravenous fluid and bowel rest at least up to 5 days until clinical symptom and sign were stabilized. And then the patient discharge until oral intake was tolerated.

In antibiotics group, the treatment was initiated with an intravenous combination of a third generation cephalosporin or quinolone and metronidazole until oral intake was tolerated. Oral antibiotics such as cefpodoxime together with metronidazole were initiated subsequently on the ward. The total duration of antibiotic treatment was an expected average 10days.

Patients in both group were re-visited outpatient clinic after an expected average 7 days for check-up of serology test (including complete blood count and C-reactive protein), and after an expected average 6 weeks for CT. If the patients did not re-visit outpatient clinic, we checked the call.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 132
Est. completion date February 2018
Est. primary completion date November 2016
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- Right-sided colonic diverticulitis

- Uncomplicated diverticulitis

Exclusion Criteria:

- Pregnancy

- Refuse to investigation

- Immunosuppressive therapy or immunologic incompetence

- Colonic diverticulitis except right-sided diverticulitis

- Complicated diverticulitis

- Disorder of psychology or cognition

- Allergic reaction to antibiotics being used in the study (3rd generation cephalosporin, quinolone, metronidazole)

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Cephalosporin + Metronidazole
intravenous antibiotics injection (3rd generation cephalosporin + metronidazole)and then change to oral antibiotics (3rd generation cephalosporin+ metronidazole) (an expected average 10 days)

Locations

Country Name City State
Korea, Republic of Department of Surgery, Dongtan Sacred Heart Hospital, Hallym University College of Medicine Hwaseong-Si Gyeonggi-Do

Sponsors (1)

Lead Sponsor Collaborator
Dongtan Sacred Heart Hospital

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Treatment Failure advancement or recurrence diverticulitis at the same site. 4-6 weeks Yes
Secondary length of hospital stay at first admission for diverticulitis up to 2 weeks No
Secondary total cost of hospitalization for diverticulitis length of hospital stay up to 2 weeks No
See also
  Status Clinical Trial Phase
Recruiting NCT01831323 - Evaluation of the Metabolome in Diverticular Disease N/A